Cidofovir: A Strategic Guide for API Buyers and Compounding Pharmacists
Few antiviral agents occupy a niche as distinctive as cidofovir.
Approved in 1996 to treat cytomegalovirus retinitis in patients with AIDS, this cytidine nucleotide analog has quietly expanded its reach across some of the most challenging DNA virus infections in immunocompromised hosts.
Today, cidofovir’s off‑label utility – from adenovirus and BK virus disease to topical therapy for human papillomavirus – fuels steady demand among compounding pharmacists, hospital pharmacies, and pharmaceutical manufacturers worldwide.
Yet cidofovir is not a straightforward molecule. Its dose‑limiting nephrotoxicity, mandatory co‑administration with probenecid, and complex preparation requirements create a landscape where deep knowledge directly translates into clinical success and commercial opportunity.
This comprehensive resource is built for the professionals who handle cidofovir at every stage of the supply chain: the API importer evaluating a new line, the quality‑assurance manager verifying a certificate of analysis, the compounding pharmacist designing a sterile preparation, and the procurement director seeking a reliable, long‑term partner.
We will move far beyond the standard drug monograph, diving into the science that makes cidofovir indispensable, the practicalities of compounding it safely, and the supply‑chain intelligence that separates top‑tier API providers from the rest.
Whether you are formulating a sterile intravitreal injection, scaling up a topical cream, or simply ensuring your next shipment meets the strictest pharmacopeial standards, the insights that follow are designed to give you a decisive edge.
What is Cidofovir?
Cidofovir (brand name Vistide) is a synthetic acyclic nucleoside phosphonate with the chemical formula C₈H₁₄N₃O₆P and CAS number 113852-37-2. (Different cas number for cidofovir monohydrate)
Its unique structure – incorporating a phosphonate group directly attached to the acyclic side chain – means it bypasses the initial phosphorylation step that limits many nucleoside analogs, such as acyclovir and ganciclovir.
Because cidofovir already carries a phosphonate equivalent, cellular enzymes convert it directly to its active diphosphate form, cidofovir diphosphate, which then serves as a potent inhibitor and alternative substrate for viral DNA polymerases.
From a pharmaceutical chemistry perspective, cidofovir is a white to off‑white crystalline powder that is highly soluble in water.
It is commercially available as a concentrated sterile solution for intravenous infusion (75 mg/mL) under the brand name Vistide, manufactured by Gilead Sciences.
However, as the original Vistide supply lines become increasingly limited and generic API manufacturers enter the market, the ability to source high‑purity cidofovir active pharmaceutical ingredient (API) directly has become critically important for compounding pharmacies and hospital cleanrooms.
This shift places a premium on understanding the molecule’s physical and chemical stability, pharmacopeial specifications, and handling requirements.
Cidofovir is classified as a hazardous drug due to its teratogenic, embryotoxic, and carcinogenic potential in animal models, as well as its dose‑related nephrotoxicity in humans.
The National Institute for Occupational Safety and Health (NIOSH) includes cidofovir on its List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, which triggers specific containment and engineering control requirements during compounding.
For any pharmacy or manufacturer, this designation directly influences facility design, personal protective equipment protocols, and waste disposal – topics we will explore in depth later.
Understanding cidofovir at the molecular and regulatory levels sets the stage for everything that follows: its unique therapeutic profile, why it resists certain resistance mechanisms, and why sourcing a GMP‑grade, thoroughly characterized API is non‑negotiable.
What is Cidofovir Used For?
Cidofovir’s regulatory label tells only part of the story. The U.S. Food and Drug Administration (FDA) approved intravenous cidofovir for the treatment of cytomegalovirus (CMV) retinitis in adults with acquired immunodeficiency syndrome (AIDS).
This indication remains the cornerstone of its licensed use, and in this setting, cidofovir has proven sight‑saving when first‑line agents such as ganciclovir are ineffective or contraindicated.
Yet cidofovir’s true clinical footprint extends far beyond the label, driven by its broad activity against virtually all double‑stranded DNA viruses.
In bone marrow and solid organ transplant units, cidofovir is a rescue therapy for adenovirus infections that can quickly become fatal in profoundly immunosuppressed patients.
For hematopoietic stem cell transplant recipients suffering from BK virus‑associated hemorrhagic cystitis, intravesical or low‑dose systemic cidofovir has emerged as a key intervention, often when no other validated treatment exists.
It has been used experimentally against JC virus‑associated progressive multifocal leukoencephalopathy (PML) and against severe mucocutaneous herpes simplex virus infections resistant to acyclovir and foscarnet.
Perhaps the most visible off‑label role for cidofovir in the community pharmacy setting is topical application.
Compounding pharmacists prepare cidofovir creams, gels, or solutions at concentrations typically ranging from 1% to 3% to treat anogenital warts caused by human papillomavirus, molluscum contagiosum, and even recalcitrant verruca vulgaris.
This dermatological use leverages cidofovir’s direct antiviral effect on infected keratinocytes while largely avoiding systemic toxicity.
Demand for these compounded preparations has grown steadily, creating a parallel market for cidofovir API that meets pharmaceutical quality requirements but is intended for topical rather than parenteral use.
For pharmaceutical manufacturers and API importers, this diversified demand landscape is highly relevant.
A supplier that understands both the sterile injectable and dermatological compounding segments can offer targeted solutions – such as different packaging sizes, stability data packages tailored to each use case, and documentation tailored to the end user’s regulatory environment.
How Does Cidofovir Work? (Mechanism of Action)
Cidofovir’s mechanism is elegantly efficient.
After cells take it up via fluid‑phase endocytosis, host cellular kinases sequentially phosphorylate the drug to its active form, cidofovir diphosphate.
This active metabolite structurally resembles deoxycytidine triphosphate (dCTP) and acts as a competitive inhibitor of viral DNA polymerase.
More importantly, it is incorporated into the growing viral DNA chain, leading to chain termination after the addition of just two further nucleotides.
The result is a potent, irreversible block to viral genome replication.
Two features of this mechanism deserve special attention from a clinical and sourcing perspective.
First, because cidofovir’s activation relies solely on cellular kinases and not on virus‑encoded enzymes such as thymidine kinase, mutations in viral thymidine kinase – a common route of resistance to acyclovir and ganciclovir – do not affect cidofovir’s activity.
This makes cidofovir particularly valuable for resistant viral strains. Second, the intracellular half‑life of cidofovir diphosphate is remarkably long, about 17 to 65 hours, and its antiviral effect persists much longer than the parent drug’s plasma half‑life.
This pharmacokinetic property allows cidofovir to be dosed once weekly during induction and every other week during maintenance. This dosing convenience can improve adherence in complex patient populations.
It is also critical to understand probenecid’s role in this equation.
Cidofovir is eliminated renally via active tubular secretion. By inhibiting the organic anion transporters responsible for this secretion, probenecid reduces the intracellular concentration of cidofovir in renal tubular cells, thereby significantly mitigating its nephrotoxic potential.
The standard regimen of intravenous cidofovir therefore always includes probenecid and aggressive saline hydration, a combination that defines administration logistics in any hospital or infusion center.
What Are the Side Effects of Cidofovir?
Nephrotoxicity is the adverse effect that dominates every clinical decision involving systemic cidofovir.
In the pivotal clinical trials that led to its approval, up to 53% of patients developed proteinuria, and up to 24% exhibited an elevation in serum creatinine.
More profoundly, Fanconi‑like syndromes with glucosuria, phosphaturia, and bicarbonate wasting have been reported, reflecting direct damage to the proximal tubular cells.
This renal toxicity is dose‑dependent and usually reversible if detected early. Still, it requires rigorous monitoring: document baseline serum creatinine and urine protein before each infusion, and withhold or discontinue the drug according to clearly defined thresholds.
Neutropenia is the second major dose‑limiting toxicity.
In the same studies, approximately 15% of patients developed severe neutropenia (absolute neutrophil count below 500 cells/µL).
For immunocompromised patients already at risk of infection, this consequence warrants careful hematological surveillance and, in some cases, growth factor support.
Ocular effects are especially relevant when cidofovir is administered intraocularly or when systemic exposure is high.
Hypotony (decreased intraocular pressure) and anterior uveitis have occurred in both the treated and the contralateral eye, leading to the recommendation that regular ophthalmic examinations be integrated into the treatment plan.
Additional systemic effects include nausea, vomiting, metabolic acidosis, and alopecia.
A particularly instructive observation for compounders is that many of these adverse effects are significantly attenuated or absent when cidofovir is applied topically.
This therapeutic window – systemic potency versus local tolerability – is precisely what makes compounded cidofovir creams such an attractive option for dermatologic viral diseases.
However, even with topical application, clinicians must counsel patients about possible local irritation, burning, and, in rare instances, systemic absorption if applied to large surface areas or mucosal sites.
From a manufacturing and compounding standpoint, the side‑effect profile highlights why purity matters.
Even trace impurities in an API that affect renal clearance pathways could theoretically compound toxicity.
Selecting a cidofovir API supplier that can provide detailed impurity profiles, including residual solvents and heavy metals, with levels below ICH Q3C and Q3D thresholds, is an essential risk‑mitigation step.
Cidofovir Dosage and Administration
Precise cidofovir dosing is inseparable from patient safety.
The FDA‑approved regimen for CMV retinitis calls for an induction phase of 5 mg/kg administered as a one‑hour intravenous infusion once weekly for two consecutive weeks, followed by a maintenance phase of 5 mg/kg every two weeks.
Each dose must be accompanied by oral probenecid: 2 grams three hours before the infusion, and 1 gram at two and eight hours after the completion of the infusion, for a total of 4 grams of probenecid per treatment cycle.
In parallel, patients must receive at least 1 liter of 0.9% sodium chloride intravenously over 1 to 2 hours immediately before the cidofovir infusion, with additional hydration as tolerated.
For compounding pharmacists, preparing a cidofovir intravenous admixture from a concentrated stock solution or directly from an API powder requires meticulous aseptic technique and intimate knowledge of the drug’s compatibility.
Withdraw the Vistide concentrate (75 mg/mL) and dilute it in 100 mL of 0.9% sodium chloride injection.
The final concentration must not exceed 5 mg/mL to minimize local irritation and phlebitis.
When compounding from a pure cidofovir powder, the pharmacist must first prepare a concentrated stock solution in sterile water for injection, ensuring complete dissolution, then filter it through a 0.22‑micron sterile filter before transferring the calculated volume to the infusion bag.
All steps must occur within a certified Class II biological safety cabinet or a compounding aseptic containment isolator, with personnel wearing appropriate chemotherapy gloves, gowns, and respiratory protection as indicated.
Intravitreal administration is a completely different modality. Typically, 20 micrograms in 0.1 mL of preservative‑free sterile solution is injected directly into the vitreous cavity every five to six weeks.
This requires advanced aseptic processing and must be prepared in an ISO Class 5 environment, in accordance with USP <797> standards for high‑risk compounded sterile preparations.
Even slight deviations in dose, pH, or osmolality can provoke severe intraocular inflammation.
Topical administration is less regulated but no less demanding.
A typical compounded formulation might be cidofovir 1% to 3% in a cream base, such as hydrophilic petrolatum, or in a gel vehicle.
When preparing such a product, the compounding pharmacist must account for cidofovir’s physicochemical stability in the chosen base, the preservative system, and the beyond-use date.
While the FDA’s framework for traditional pharmacy compounding under section 503A (and outsourcing facilities under 503B) allows for this practice, the pharmacist assumes full responsibility for quality, potency, and safety.
How Long Does Cidofovir Stay in Your System?
This question is best answered by distinguishing between the parent drug and its active metabolite.
After a standard one‑hour intravenous infusion, cidofovir’s plasma concentration declines biphasically, with a terminal elimination half‑life of approximately 2.4 to 3.2 hours.
However, the intracellular cidofovir diphosphate that mediates the antiviral effect persists with a half‑life ranging from 17 to 65 hours, and the active metabolite remains measurable in cells for several days after a dose.
This discrepancy between plasma and intracellular kinetics explains why the drug can be given at weekly or biweekly intervals while maintaining continuous suppression of viral replication.
In patients with normal renal function, approximately 80% to 100% of the dose is excreted unchanged in the urine within 24 hours, primarily via glomerular filtration and active tubular secretion.
When probenecid is co‑administered, renal clearance is slowed, and systemic exposure increases.
This interaction is actually therapeutic: it moderates the intra‑renal concentration of cidofovir while maintaining plasma levels within a safe range.
The consequence for drug‑drug interaction management is that any medication that interferes with renal tubular function or probenecid’s blocking effect will alter cidofovir’s residence time and toxicity profile.
For topical application, systemic absorption is generally minimal when the product is applied to intact skin.
However, if applied to large mucosal areas or to eroded lesions, measurable plasma concentrations can be achieved, and the intracellular persistence concept still applies.
Therefore, even with external use, careful consideration of the total amount dispensed, the application area, and the frequency is warranted – a factor compounders must communicate clearly to prescribers and patients.
Cidofovir Precautions and Drug Interactions
Managing cidofovir therapy requires the same tight coordination as a clinical trial.
The absolute contraindication is pre‑existing renal impairment, defined as a serum creatinine greater than 1.5 mg/dL, a calculated creatinine clearance of 55 mL/min or lower, or clinically significant proteinuria (≥ 100 mg/dL or 2+ proteinuria on urinalysis).
Before each dose, repeat serum creatinine and urine dipstick tests must be obtained, and the results reviewed before proceeding.
If the creatinine level rises by 0.3-0.4 mg/dL above baseline, reduce the maintenance dose.
If it rises by 0.5 mg/dL or more, or if 3+ proteinuria develops, discontinue cidofovir.
Concomitant administration of other nephrotoxic agents is prohibited.
This long list includes aminoglycosides, amphotericin B, foscarnet, intravenous pentamidine, nonsteroidal anti‑inflammatory drugs, and even high‑dose acyclovir.
Because many patients requiring cidofovir are already on multiple antimicrobial regimens, a thorough medication reconciliation with particular attention to renal stressors is indispensable.
Probenecid, while protective, creates its own cascade of interactions.
As an inhibitor of organic anion transporters and uridine diphosphate glucuronosyltransferase enzymes, probenecid raises serum concentrations of multiple drugs, including penicillins, cephalosporins, methotrexate, and several antiretrovirals such as zidovudine.
Patients on zidovudine should temporarily discontinue the drug or reduce the dose by 50% on the day of cidofovir administration to avoid severe hematologic toxicity.
Similarly, the combination of probenecid and high‑dose acetaminophen may lead to a buildup of toxic metabolites, requiring caution.
For pharmacists and clinicians, handling cidofovir also warrants precautions.
As a hazardous drug, it should be prepared in accordance with USP <800> guidelines, using closed‑system transfer devices when possible, and any spills must be managed with a spill kit appropriate for cytotoxic agents.
These requirements directly affect the layout, equipment budget, and training programs of any compounding operation, reinforcing the need for a reliable, high‑quality cidofovir API source that delivers consistent batch‑to‑batch safety profiles.
Compounding Guidelines for Cidofovir
Compounding cidofovir is a high‑stakes activity that sits at the intersection of regulatory compliance, pharmaceutical science, and clinical art.
This section serves as a practical reference for compounding pharmacists and quality professionals establishing or refining cidofovir compounding protocols.
Regulatory Framework and Classification
Under both USP <797> and <800>, cidofovir is categorized as a hazardous drug.
Therefore, all manipulations of the API powder or the concentrated solution must be carried out in a certified containment primary engineering control, typically a Class II Type B biosafety cabinet or a compounding aseptic containment isolator.
The cleanroom suite must meet ISO Class 7 or better requirements for the buffer area, with an ISO Class 5 environment for direct compounding.
Personnel must complete hazardous drug handling competency assessments and wear two pairs of chemotherapy‑rated gloves, impervious disposable gowns, and full-face protection when splashing is possible.
Closed‑system transfer devices are strongly recommended during the dilution and transfer steps.
Receiving and Storing the API
When a bulk cidofovir API powder arrives from the supplier, the receiving pharmacist should verify that the container closure is intact, that the temperature monitor (if included) confirms storage within the labeled range, and that the certificate of analysis meets the pharmacy’s adopted specifications.
Typically, cidofovir API is stored at 20‑25°C, protected from light and moisture.
An aliquot should be taken for in‑house identity testing – at a minimum, melting point, infrared spectroscopy, or a validated HPLC method – before releasing the batch for clinical use.
Accept only the API that meets all labeled purity claims, typically ≥99.0% on an anhydrous basis.
Sterile Compounding for Intravenous and Intravitreal Use
For a standard intravenous dose, a pharmacist would first calculate the amount of cidofovir powder required to achieve the prescribed dose, using the anhydrous equivalent weight.
The powder is dissolved in an appropriate volume of sterile water for injection to prepare a stock solution of known concentration (typically 75 mg/mL) to mimic the Vistide concentrate.
Sterile-filter this solution through a 0.22‑micron PVDF or PES membrane into a sterile receiving vessel.
The filtered concentrate is then aseptically transferred into a 100 mL normal saline infusion bag, with attention to final drug concentration (≤5 mg/mL) and thorough mixing.
Visually inspect the compounded admixture for particulate matter, label it, and assign a beyond‑use date.
Current data suggest that cidofovir admixtures in 0.9% sodium chloride are physically and chemically stable for up to 24 hours when refrigerated at 2‑8°C. Still, each pharmacy should confirm stability using a stability‑indicating assay under its own conditions.
Intravitreal doses demand an additional layer of care.
The compounded solution must be preservative‑free, isotonic, and close to physiological pH (approximately 7.4). Many pharmacies aliquot the filtered stock into individual sterile syringes in a horizontal laminar airflow hood after performing a final sterile filtration step.
The beyond‑use date for an intravitreal preparation, if stored frozen, can extend to a few weeks based on published stability data. Still, any robust sterility assurance program must support any such extension.
Topical Preparations
Compounding a topical cidofovir cream follows a different workflow but is no less rigorous.
The cidofovir powder is incorporated into a base by geometric dilution; careful attention is paid to the vehicle’s pH and to penetration enhancers that might inadvertently increase systemic absorption.
Typical bases include hydrophilic ointment, Lipoderm®, or a poloxamer gel, each selected for its release characteristics and cosmetic acceptability.
Verify chemical stability in the chosen base at the target concentration over the intended period of use.
Preservatives such as parabens or phenoxyethanol may be added to protect against microbial growth, but they must be demonstrated to be compatible with the active ingredient.
Quality Control and Documentation
Every batch of compounded cidofovir – whether injectable or topical – should undergo end‑product testing.
For sterile preparations, sterility testing per USP <71> and endotoxin testing per USP <85> are mandatory if the beyond‑use date exceeds USP limits for low‑risk compounding.
An assay (HPLC) confirms that the cidofovir concentration remains within ±10% of the labeled amount.
Maintain full documentation, including master formulation records, compounding records, and quality control data, and keep it available for inspection by state boards of pharmacy or the FDA.
A trusted Cidofovir API supplier will support the compounding pharmacist at every step: providing a comprehensive certificate of analysis that includes microbial limits, residual solvents, and elemental impurities; sharing forced‑degradation data to help develop stability‑indicating assays; and offering technical support to troubleshoot formulation challenges.
This partnership is the foundation for safe, effective compounded cidofovir products.
Global Sourcing Tips for Cidofovir API
For pharmaceutical manufacturers, importers, and compounding pharmacies that source cidofovir API on the international market, success hinges on far more than price per kilogram.
The difference between a reliable, audit‑ready supply chain and a costly regulatory setback often comes down to how thoroughly you vet your potential partner.
Here, we distill the critical considerations that should shape every sourcing decision.
1. Demand Full Transparency on the Drug Master File (DMF)
If you intend to use cidofovir in a product that requires FDA or EMA approval, the API manufacturer should have an active Type II DMF with the relevant authority. A Letter of Authorization to cross-reference the DMF is non-negotiable. Even for 503A or 503B compounding operations that do not formally require a DMF, a supplier’s willingness to maintain a DMF signals a commitment to cGMP and long‑term accountability. Request the DMF number and verify its status.
2. Scrutinize the Certificate of Analysis Beyond Purity
While a purity of ≥99.0% by HPLC is a baseline expectation, the complete COA must include detailed specifications for known and unknown impurities, residual solvents per USP <467> or equivalent, and elemental impurities per USP <232>/<233> or ICH Q3D.
For cidofovir, pay special attention to phosphate‑related impurities, which may arise during synthesis, and any organic volatile impurities.
A supplier that tests against the latest pharmacopeial monographs – and can provide chromatograms and method validation data – separates itself from traders who relabel products.
3. Evaluate Manufacturing Site and Quality Systems
Request a copy of the current cGMP certificate issued by the competent regulatory authority (FDA, EDQM, PMDA, etc.), and ensure the scope explicitly covers cidofovir API.
A written quality agreement, signed by both parties, should define responsibilities for change control, deviation management, and ongoing stability testing. If possible, conduct or commission a virtual or on‑site audit of the facility, with particular focus on the cytotoxic containment capabilities and the analytical laboratory.
4. Assess Supply Chain Security and Logistics
Cidofovir API is typically shipped in sealed, moisture‑proof containers at controlled room temperature.
Confirm that the supplier’s standard shipping conditions include temperature loggers and that the product’s stability data support any temperature excursions.
Negotiate packaging sizes that align with your production needs – small‑volume compounders may prefer 1‑gram or 5‑gram aliquots, while manufacturers may require 100‑gram to kilogram‑scale lots.
Clarify the lead time, minimum order quantities, and Incoterms. Customs clearance for an antiviral API can trigger additional scrutiny, so work with a supplier experienced in providing the necessary export documentation, including certificates of origin, free‑sale certificates, and end‑use declarations.
5. Compare Pricing with a Total Cost of Ownership Lens
The lowest price per gram is irrelevant if you incur costs for retesting, rejection, or batch failure.
Build a true cost model that includes shipping, insurance, import duties, in‑house analytical testing, and the financial risk of supply interruption.
A supplier that offers a slightly higher unit price but includes comprehensive analytical support, dedicated account management, and batch reservation programs may deliver far greater value over the lifecycle of the commercial relationship.
6. Niche Supply for Compounding Pharmacies
Compounding pharmacies often require smaller quantities of cidofovir API with the same rigorous quality attributes as the industrial‑scale lots.
Seek suppliers that specifically serve the pharmaceutical compounding market and provide documentation packages tailored to a state‑licensed pharmacy’s needs, including certificates of analysis that reference the relevant USP monograph, USP <800> safety data, and product use statements.
A supplier that understands the unique regulatory pressures of 503A and 503B compounding can become a strategic partner, not just a vendor.
7. Look Ahead to Future Regulatory Trends
The regulatory environment for compounded products is tightening globally. Starting with a cidofovir API that meets the most stringent standards today positions your operation to adapt seamlessly as new guidance or pharmacopeial revisions emerge.
Ask your potential supplier about their impurity control strategy, their approach to nitrosamine risk assessments, and their plan to comply with evolving Annex 1 requirements for sterile products.
The answer will reveal whether they are a proactive, innovation‑driven manufacturer or a follower that may struggle to keep pace.
Frequently Asked Questions About Cidofovir
Can cidofovir be given orally?
No. Cidofovir has very poor oral bioavailability and is only approved for intravenous or intravitreal administration. Oral brincidofovir was designed to overcome this limitation but is not a direct substitute for all current cidofovir indications.
What is the shelf life of cidofovir API powder?
When stored at 20‑25°C and protected from light and moisture, cidofovir API has remained stable for 24 to 36 months in long‑term stability studies. Retest dates, not expiration dates, are often assigned to bulk API, and the supplier should provide a stability commitment.
Is a prescription always required for cidofovir compounded cream?
Yes. Cidofovir is a prescription‑only medication. All compounded preparations, regardless of route, must be dispensed against a valid prescription from a licensed prescriber.
Can cidofovir API be shipped internationally?
Yes, provided that the exporter and importer comply with the applicable customs and pharmaceutical regulations of both the exporting and importing countries. A reliable supplier will provide export documentation, including a certificate of analysis, a certificate of origin, and any required import permits.
Does cidofovir require cold‑chain storage?
No. The API and the Vistide concentrate are stored at controlled room temperature (20‑25°C). However, refrigerate reconstituted solutions and use them within 24 hours unless stability data support longer storage.
Conclusion
Cidofovir offers a rare combination of an established, indispensable antiviral and a growing, diversifying market.
Its broad-spectrum activity against DNA viruses, its unique resistance profile, and its adaptability to both systemic and local therapy ensure it will remain a fixture in hospital formularies and compounding pharmacies for years to come.
Yet the very properties that make cidofovir so valuable – its potency, its need for precise handling, its potential for toxicity – place extraordinary demands on the professionals who procure, formulate, and dispense it.
For pharmaceutical manufacturers and API importers, the business case for a robust cidofovir supply line is compelling.
The specialty niche shields it from commoditization, while the expanding off‑label applications in transplant medicine and dermatology create sustained, predictable demand.
Success hinges on selecting a supplier that offers more than a raw material; you need a partner that delivers GMP‑certified purity, exhaustive documentation, regulatory insight, and the flexibility to meet both industrial‑scale and boutique compounding needs.
For compounding pharmacists, mastering cidofovir means integrating hazardous drug safety, advanced aseptic technique, and formulation science into a single, seamless process.
The patients who rely on your cidofovir products are often among the most vulnerable – transplant recipients, individuals living with advanced HIV, children with persistent warts – and they deserve formulations that are as safe and effective as any commercially manufactured medication.
That standard begins with the API you choose and is sustained by the quality systems you build around it.
We invite you to explore our cidofovir API portfolio and discover the difference that a partner‑first, quality‑driven supplier can make.
Whether you are scaling up production or launching a new compounded therapy, we are ready to support you with the technical data, regulatory documentation, and dependable supply chain that your work demands.
The future of antiviral care depends on the collaborations we forge today, and we are committed to being part of your success.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
